Amgen Urges Full Fed. Circ. Hearing On Repatha Patents

Law360, Washington (December 7, 2017, 5:08 PM EST) -- Drugmaker Amgen asked the Federal Circuit on Wednesday for an en banc rehearing of a decision that revived a challenge to its patents for Repatha, an antibody-based cholesterol treatment, saying a panel abandoned precedent by rejecting a previously used test for patentability of such drugs and finding admissible evidence that post-dates the challenged patents.

In striking down a lower court’s ruling upholding patents for Repatha, a three-judge panel invalidated the “newly characterized antigen test,” which has been cited in multiple Federal Circuit and U.S. Patent and...
To view the full article, register now.